Thermo Fisher Scientific, Eli Lilly ink agreement to develop companion diagnostic for identifying patients who could benefit from Lilly's RET inhibitor, which recently posted strong Phase 1/2 data
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.